Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort pMDI 40/2.25 µg twice daily with vs without spacer in children with asthma
2007-002722-29Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of budesonide in asthma (2 arms), sponsored by AstraZeneca. Primary endpoint: 24-hour urine free cortisol excretion. Started Jul 2007; status: completed.
02
Drugs
budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on 2007-002722-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002722-29.